Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 710 participants.
Also called NCT07715929
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 710 participants
- Sponsor
- Yunlong Wang
- Registry
-
NCT07715929
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07715929. Randomized; single masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
- Acronym
- TEAR-AF
- Condition
- Atrial Fibrillation
- Condition
- Obesity & Overweight
- Condition
- Catheter Ablation
- Intervention (Drug)
- Tirzepatide
- Intervention (Behavioral)
- Structured Lifestyle Intervention
- Lead sponsor
- Yunlong Wang
Record details
- Record id
cardio:ct-nct07715929- Content hash
5e74c03034a187281e339f0ae2aaf42e14bffe9127066d3b7afcd0036ee97236